Trial
NCT05019742
Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Shanghai Pharma Biotherapeutics USA Inc.
Collaborators
—
Condition
Ulcerative Colitis
Intervention
SPH3127
Why stopped
Shanghai Pharma Biotherapeutics USA Inc. experienced difficulty in recruiting clinical research sites and in enrolling patients with ulcerative colitis, and consequently, the study was terminated due to futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-26